Daniel C. Berwick

1. The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play
   2021/05/29 by Sonia Azeggagh, Daniel C. Berwick · 17 citations
   Medicine · #Parkinson's Disease Mechanisms and Treatments #Alzheimer's disease research and treatments